These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31450748)

  • 1. Towards the Oral Treatment of Ileo-Colonic Inflammatory Bowel Disease with Infliximab Tablets: Development and Validation of the Production Process.
    Gareb B; Posthumus S; Beugeling M; Koopmans P; Touw DJ; Dijkstra G; Kosterink JGW; Frijlink HW
    Pharmaceutics; 2019 Aug; 11(9):. PubMed ID: 31450748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of novel zero-order release budesonide tablets for the treatment of ileo-colonic inflammatory bowel disease and comparison with formulations currently used in clinical practice.
    Gareb B; Dijkstra G; Kosterink JGW; Frijlink HW
    Int J Pharm; 2019 Jan; 554():366-375. PubMed ID: 30414898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastrointestinal pH and Transit Time Profiling in Healthy Volunteers Using the IntelliCap System Confirms Ileo-Colonic Release of ColoPulse Tablets.
    Maurer JM; Schellekens RC; van Rieke HM; Wanke C; Iordanov V; Stellaard F; Wutzke KD; Dijkstra G; van der Zee M; Woerdenbag HJ; Frijlink HW; Kosterink JG
    PLoS One; 2015; 10(7):e0129076. PubMed ID: 26177019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a zero-order sustained-release tablet containing mesalazine and budesonide intended to treat the distal gastrointestinal tract in inflammatory bowel disease.
    Gareb B; Eissens AC; Kosterink JGW; Frijlink HW
    Eur J Pharm Biopharm; 2016 Jun; 103():32-42. PubMed ID: 27000751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulation and In Vitro Evaluation of Pellets Containing Sulfasalazine and Caffeine to Verify Ileo-Colonic Drug Delivery.
    Broesder A; Bircan SY; de Waard AB; Eissens AC; Frijlink HW; Hinrichs WLJ
    Pharmaceutics; 2021 Nov; 13(12):. PubMed ID: 34959267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ColoPulse tablets perform comparably in healthy volunteers and Crohn's patients and show no influence of food and time of food intake on bioavailability.
    Maurer JM; Schellekens RC; van Rieke HM; Stellaard F; Wutzke KD; Buurman DJ; Dijkstra G; Woerdenbag HJ; Frijlink HW; Kosterink JG
    J Control Release; 2013 Dec; 172(3):618-24. PubMed ID: 24096020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surface Engineering Methods for Powder Bed Printed Tablets to Optimize External Smoothness and Facilitate the Application of Different Coatings.
    Nguyen KTT; Zillen D; van Heijningen FFM; van Bommel KJC; van Ee RJ; Frijlink HW; Hinrichs WLJ
    Pharmaceutics; 2023 Aug; 15(9):. PubMed ID: 37765163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formulation of a 3D Printed Biopharmaceutical: The Development of an Alkaline Phosphatase Containing Tablet with Ileo-Colonic Release Profile to Treat Ulcerative Colitis.
    Nguyen KTT; Heijningen FFM; Zillen D; van Bommel KJC; van Ee RJ; Frijlink HW; Hinrichs WLJ
    Pharmaceutics; 2022 Oct; 14(10):. PubMed ID: 36297614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and potential application of an oral ColoPulse infliximab tablet with colon specific release: A feasibility study.
    Maurer JM; Hofman S; Schellekens RC; Tonnis WF; Dubois AO; Woerdenbag HJ; Hinrichs WL; Kosterink JG; Frijlink HW
    Int J Pharm; 2016 May; 505(1-2):175-86. PubMed ID: 26997425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 1-year prospective study of the effect of infliximab on bone metabolism in inflammatory bowel disease patients.
    Veerappan SG; Healy M; Walsh B; O'Morain CA; Daly JS; Ryan BM
    Eur J Gastroenterol Hepatol; 2016 Nov; 28(11):1335-44. PubMed ID: 27508327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays.
    Van Stappen T; Brouwers E; Tops S; Geukens N; Vermeire S; Declerck PJ; Gils A
    Ther Drug Monit; 2015 Aug; 37(4):479-85. PubMed ID: 25525757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paradoxical articular manifestations in patients with inflammatory bowel diseases treated with infliximab.
    Thiebault H; Boyard-Lasselin P; Guignant C; Guillaume N; Wacrenier A; Sabbagh C; Rebibo L; Brazier F; Meynier J; Nguyen-Khac E; Dupas JL; Goëb V; Fumery M
    Eur J Gastroenterol Hepatol; 2016 Aug; 28(8):876-81. PubMed ID: 27101404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab.
    Orfanoudaki E; Gazouli M; Foteinogiannopoulou K; Theodoraki E; Legaki E; Romanos I; Mouzas I; Koutroubakis IE
    Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):187-191. PubMed ID: 30543573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD.
    Frederiksen MT; Ainsworth MA; Brynskov J; Thomsen OO; Bendtzen K; Steenholdt C
    Inflamm Bowel Dis; 2014 Oct; 20(10):1714-21. PubMed ID: 25069030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A rapid assay for on-site monitoring of infliximab trough levels: a feasibility study.
    Corstjens PL; Fidder HH; Wiesmeijer KC; de Dood CJ; Rispens T; Wolbink GJ; Hommes DW; Tanke HJ
    Anal Bioanal Chem; 2013 Sep; 405(23):7367-75. PubMed ID: 23836086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab quantitation in human plasma by liquid chromatography-tandem mass spectrometry: towards a standardization of the methods?
    Jourdil JF; Lebert D; Gautier-Veyret E; Lemaitre F; Bonaz B; Picard G; Tonini J; Stanke-Labesque F
    Anal Bioanal Chem; 2017 Feb; 409(5):1195-1205. PubMed ID: 27826630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-α biologicals and an Infliximab-biosimilar.
    Buurman DJ; Blokzijl T; Festen EAM; Pham BT; Faber KN; Brouwer E; Dijkstra G
    PLoS One; 2018; 13(12):e0208922. PubMed ID: 30533022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of infliximab on inflammatory bowel disease with Takayasu arteritis: case series and review of the literature.
    Minami N; Nakase H; Yoshino T; Yamada S; Toyonaga T; Honzawa Y; Matsuura M; Chiba T
    Clin J Gastroenterol; 2013 Jun; 6(3):226-30. PubMed ID: 26181600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term clinical outcome after infliximab discontinuation in patients with inflammatory bowel disease.
    Lee JM; Kim YJ; Lee KM; Yoon H; Lee BI; Kim DB; Kang D
    Scand J Gastroenterol; 2018; 53(10-11):1280-1285. PubMed ID: 30351977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fiber optic-SPR platform for fast and sensitive infliximab detection in serum of inflammatory bowel disease patients.
    Lu J; Van Stappen T; Spasic D; Delport F; Vermeire S; Gils A; Lammertyn J
    Biosens Bioelectron; 2016 May; 79():173-9. PubMed ID: 26706938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.